Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Neumora Therapeutics Inc (NASDAQ: NMRA) closed at $2.56 down -0.78% from its previous closing price of $2.58. In other words, the price has decreased by -$0.78 from its previous closing price. On the day, 1.21 million shares were traded. NMRA stock price reached its highest trading level at $2.635 during the session, while it also had its lowest trading level at $2.4.
Ratios:
For a deeper understanding of Neumora Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.85 and its Current Ratio is at 6.85. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.15.
BofA Securities Downgraded its Buy to Underperform on April 02, 2025, while the target price for the stock was maintained at $1.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 27 ’25 when Burow Kristina bought 1,915,700 shares for $2.61 per share. The transaction valued at 4,999,977 led to the insider holds 6,046,907 shares of the business.
ARCH Venture Partners XII, LLC bought 1,915,700 shares of NMRA for $4,999,977 on Oct 27 ’25. The 10% Owner now owns 6,046,907 shares after completing the transaction at $2.61 per share. On Oct 27 ’25, another insider, ARCH Venture Partners X, LLC, who serves as the 10% Owner of the company, bought 1,915,700 shares for $2.61 each. As a result, the insider paid 4,999,977 and bolstered with 6,046,907 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NMRA now has a Market Capitalization of 427748128 and an Enterprise Value of 220192208.
Stock Price History:
The Beta on a monthly basis for NMRA is 3.10, which has changed by -0.8123167 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, NMRA has reached a high of $14.09, while it has fallen to a 52-week low of $0.61. The 50-Day Moving Average of the stock is 29.90%, while the 200-Day Moving Average is calculated to be 80.64%.
Shares Statistics:
For the past three months, NMRA has traded an average of 1.35M shares per day and 3774470 over the past ten days. A total of 161.95M shares are outstanding, with a floating share count of 54.09M. Insiders hold about 67.63% of the company’s shares, while institutions hold 21.88% stake in the company. Shares short for NMRA as of 1760486400 were 6788203 with a Short Ratio of 5.02, compared to 1757894400 on 6417308. Therefore, it implies a Short% of Shares Outstanding of 6788203 and a Short% of Float of 11.560000500000001.
Earnings Estimates
The market rating of Neumora Therapeutics Inc (NMRA) is currently shaped by the ongoing analysis conducted by 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.27 and low estimates of -$0.28.
Analysts are recommending an EPS of between -$1.39 and -$1.45 for the fiscal current year, implying an average EPS of -$1.42. EPS for the following year is -$1.02, with 6.0 analysts recommending between -$0.59 and -$1.62.
